- Home
- AKRO vs PRAX Comparison
AKRO vs PRAX Comparison
Compare AKRO & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AKRO | PRAX |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.0B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AKRO | PRAX |
|---|---|---|
| Price | $54.65 | $272.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 14 |
| Target Price | $73.56 | ★ $349.79 |
| AVG Volume (30 Days) | ★ 2.4M | 1.1M |
| Earning Date | 11-07-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,463,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 364.98 |
| 52 Week Low | $21.34 | $26.70 |
| 52 Week High | $58.40 | $282.99 |
Technical Indicators
Market Signals| Indicator | AKRO | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 68.63 | 67.59 |
| Support Level | $54.30 | $262.31 |
| Resistance Level | $54.70 | $282.99 |
| Average True Range (ATR) | 0.17 | 16.76 |
| MACD | -0.10 | 1.47 |
| Stochastic Oscillator | 71.07 | 86.18 |
Price Performance
Historical ComparisonAbout AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.